FibroBiologics files patent for engineered cells designed to produce GLP-1 inside body
FBLG•FibroBiologics filed a U.S. patent application for engineered cells designed to produce GLP-1 class peptides inside the body, with the aim of replacing repeated injections or pills with one-time administration.
1. Patent application details
The application covers fibroblasts or other cells formed into spheroids or organoids that secrete GLP-1, GIP or GLP-2 over time. It also describes dual or triple agonist secretion and features including immune evasion, inducible kill switches, safe-harbor gene insertion and retrievable encapsulation devices.
